PDCD1 and neoplasm: Furthermore, in a multi-national Phase II study (NCI-9742), the anti-tumor activity of nivolumab (a humanized anti-PD1 monoclonal antibody) in patients with multiply pre-treated recurrent or metastatic NPC (n=44), was evaluated.